Acromegaly
📧 Sign up to get email alerts when something new happens for Acromegaly.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2020-06-26FDA Approved: MYCAPSSA — Original Application (Chiesi USA, Inc.)
The FDA approved MYCAPSSA, an oral formulation of octreotide from Chiesi USA, representing the original approval of an oral octreotide produ…
-
CLINICAL_TRIALS trial_result · 2020-03-31Clinical Trial Update: Efficacy and Safety of Lanreotide Autogel (60, 90 or 120 mg) in Acromegalic Patients [Phase 3]
A Phase 3 trial evaluating the efficacy and safety of lanreotide autogel at 60, 90, or 120 mg in patients with acromegaly has completed.
-
FDA approval · 2020-02-03FDA Approved: OCTREOTIDE ACETATE — Supplemental Application (Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.)
FDA approved a supplemental application for octreotide acetate from Heritage Pharmaceuticals Inc. (Avet Pharmaceuticals Inc.).
-
FDA approval · 2020-02-03FDA Approved: OCTREOTIDE ACETATE — Supplemental Application (Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.)
The FDA approved a supplemental application for octreotide acetate from Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc. under …
-
FDA approval · 2019-12-13FDA Approved: BROMOCRIPTINE MESYLATE — Supplemental Application (ANI Pharmaceuticals, Inc.)
FDA approved a Supplemental Application for Bromocriptine Mesylate by ANI Pharmaceuticals, Inc. The provided excerpt does not specify a new …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2019-12-04Clinical Trial Update: Pasireotide in Patients With Acromegaly Inadequately Controlled With First Generation Somatostatin Analogues [Phase 3]
Phase 3 trial evaluating pasireotide in patients with acromegaly inadequately controlled by first-generation somatostatin analogues has comp…
-
CLINICAL_TRIALS trial_result · 2019-11-22Clinical Trial Update: Effect of 120mg Somatuline Autogel at Different Dose Intervals (28, 42 or 56 Days) in Patients With Acromegaly [Phase 3]
A Phase 3 clinical trial evaluated 120 mg Somatuline Autogel given at 28, 42, or 56 day intervals in patients with acromegaly.
-
FDA approval · 2019-09-24FDA Approved: SOMAVERT — Supplemental Application (Pharmacia & Upjohn Company LLC)
The FDA approved a supplemental application for Somavert (pegvisomant) submitted by Pharmacia & Upjohn Company LLC.
-
FDA approval · 2019-09-19FDA Approved: SOMAVERT — Supplemental Application (Pharmacia & Upjohn Company LLC)
FDA approved a supplemental application for Somavert (pegvisomant) submitted by Pharmacia & Upjohn Company LLC. Somavert is used to treat ac…
-
CLINICAL_TRIALS trial_result · 2019-09-16Clinical Trial Update: Efficacy and Safety of Pasireotide LAR (Long-acting Release) in Japanese Patients With Acromegaly or Pituitary Gigantism [Phase 2]
Phase 2 trial assessing efficacy and safety of pasireotide LAR in Japanese patients with acromegaly or pituitary gigantism has been complete…
-
FDA approval · 2019-09-05FDA Approved: OCTREOTIDE ACETATE — Supplemental Application (Mylan Institutional LLC)
FDA approved a supplemental application for octreotide acetate submitted by Mylan Institutional LLC (ANDA079198). This action constitutes a …
-
FDA approval · 2019-08-16FDA Approved: SOMAVERT — Supplemental Application (Pharmacia & Upjohn Company LLC)
The FDA approved a supplemental application for Somavert (pegvisomant) submitted by Pharmacia & Upjohn Company LLC. This action updates the …
-
CLINICAL_TRIALS trial_result · 2019-08-16Clinical Trial Update: Lanreotide Autogel in Patients With Acromegaly Previously Treated With Octreotide LAR [Phase 4]
Phase 4 trial assessing lanreotide Autogel in acromegaly patients previously treated with octreotide LAR has completed.
-
CLINICAL_TRIALS trial_result · 2019-08-05Clinical Trial Update: Somatuline Autogel: Acromegaly Self/Partner Injection Study [Phase 4]
Phase 4 clinical trial update on Somatuline Autogel for acromegaly; study completed.
-
CLINICAL_TRIALS trial_result · 2019-08-02Clinical Trial Update: Efficacy and Safety Study of Varying Doses of Lanreotide Autogel in Patients With Acromegaly [Phase 2, Phase 3]
Phase 2/3 trial update evaluating varying doses of Lanreotide Autogel for acromegaly, focusing on efficacy and safety.
-
CLINICAL_TRIALS trial_result · 2019-07-09Clinical Trial Update: Growth Hormone Feedback to Insulin-like Growth Factor-I (IGF-1) and Oral Glucose Tolerance Test (OGTT) [NA]
Clinical trial update on growth hormone feedback to IGF-1 and OGTT in adults with acromegaly and type 2 diabetes mellitus; the study is comp…
-
CLINICAL_TRIALS trial_result · 2019-05-29Clinical Trial Update: Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or Acromegaly [Phase 4]
A Phase 4 clinical trial completed in 2019 evaluating management of pasireotide-induced hyperglycemia in adults with Cushing's disease or ac…
-
CLINICAL_TRIALS trial_result · 2019-05-07Clinical Trial Update: Clomiphene Citrate for Treatment of Acromegaly [Phase 2]
Phase 2 clinical trial evaluating clomiphene citrate for acromegaly has completed with results posted in 2019.
-
CLINICAL_TRIALS trial_result · 2019-04-29Clinical Trial Update: Acromegaly Treatment Quality of Life Study
A completed clinical trial assessing quality of life in acromegaly treatment, with results posted in 2019.
-
CLINICAL_TRIALS trial_result · 2019-04-25Clinical Trial Update: Study to Determine the Maximum Tolerated Dose, Safety and Tolerability of a Single Dose of Lanreotide Prolonged Release Formulation (PRF) in Subjects With Acromegaly [Phase 1, Phase 2]
Phase 1/2 trial assessing maximum tolerated dose, safety, and tolerability of a single-dose lanreotide prolonged-release formulation in adul…
-
FDA approval · 2019-04-11FDA Approved: SOMATULINE DEPOT — Supplemental Application (Ipsen Biopharmaceuticals, Inc.)
This FDA document indicates approval of a supplemental application for Somatuline Depot (lanreotide acetate) by Ipsen Biopharmaceuticals, In…
-
FDA approval · 2019-04-11FDA Approved: SANDOSTATIN — Supplemental Application (Novartis Pharmaceuticals Corporation)
The FDA approved a supplemental application for Sandostatin (octreotide acetate) from Novartis Pharmaceuticals Corporation under NDA 019667.
-
CLINICAL_TRIALS trial_result · 2019-03-08Clinical Trial Update: Assessment of BIM23B065, Given as Repeated Subcutaneous Injection in Subjects With Acromegaly [Phase 2]
Phase 2 clinical trial of BIM23B065 given as repeated subcutaneous injections in subjects with acromegaly; the study is terminated with resu…
-
FDA approval · 2019-01-29FDA Approved: SIGNIFOR — Supplemental Application (Recordati Rare Diseases, Inc.)
The FDA approved a supplemental application for Signifor (pasireotide) submitted by Recordati Rare Diseases, Inc. This action expands the dr…
-
CLINICAL_TRIALS trial_result · 2019-01-22Clinical Trial Update: Long Term Use of Somavert (Pegvisomant) For A Regulatory Post Marketing Commitment Plan
Clinical trial update reporting long-term use of pegvisomant (Somavert) for acromegaly as part of a regulatory post-marketing commitment; st…